Mental health has become one of the most urgent public health issues of the 21st century. Recent statistics from the World Health Organization (WHO) indicate that more than one billion individuals globally live with mental illnesses. Anxiety, depression, and other psychiatric disorders not only cause immense human distress but also carry a massive economic burden, both on individuals and societies as a whole. Where progress has been made in a number of countries to enhance mental health policies and programs, global services remain dramatically underfunded and fragmented, denying access to care for millions.

Mental illnesses are ubiquitous, cutting across all age, gender, and economic strata groups. Anxiety and depression are among the most prevalent disorders, and their effects extend far beyond emotional pain. They are the second global cause of long-term disability, costing money in healthcare, decreasing productivity in the workforce, and lowering quality of life. The fiscal hit is astronomical: depression and anxiety alone have been estimated to cost the international economy $1 trillion each year.

The WHO's recent publications, World Mental Health Today and Mental Health Atlas 2024—set both positive trends and important gaps in mental health services. They are powerful resources to inform national plans and influence the international conversation leading up to the 2025 United Nations High-Level Meeting on noncommunicable diseases, with a focus on mental health and well-being.

Rising Mental Health Concerns Among Young People

Younger populations face particularly intense mental health issues. Gen Z, in particular, is under unprecedented stress from social media, school pressures, and the aftereffects of the COVID-19 pandemic. A 2023 Harvard survey identified that 44% of young adults between ages 18–25 felt like they don't count to others. Further, CDC data indicate that 40% of U.S. high school students indicated they felt sad or hopeless most or all days, and 20% attempted seriously to take their own life. These figures highlight the imperative for accessible and effective mental health care among young people.

Social disruption during the pandemic, from remote learning issues to extended isolation, intensified loneliness and anxiety. Even after lockdowns lifted, many young people still face uncertainty about their futures, academic stress, and the mental health impacts of disrupted childhood or adolescence.

WHO Mental Health Report: One in Every 100 Deaths Worldwide is Caused by Suicide

Suicide continues to be a tragic consequence of mental illness. In 2021 alone, it is estimated that 727,000 individuals across the globe died by suicide, which is a major cause of death among youth. WHO experts point out that although age-specific rates for suicide have fallen worldwide by 35% from 2000 to 2021, efforts are too slow to achieve the United Nations Sustainable Development Goal to cut suicide rates by a third by 2030. The trend indicates only 12% reduction will be realized.

Alarming as it is, almost three-quarters of all suicides are in low- and middle-income countries, where there are limited mental health resources and stigma discourages individuals from going for help. Even in wealthier countries, timely and effective care is not always accessible.

Investment Gap in Mental Health Services

Investment in mental health services globally is not increasing commensurate with growing demand. Median government expenditure on mental health averages only 2% of overall health expenditures—unchanged since 2017. Inequities between nations are glaring: high-income countries can spend as much as $65 per capita on mental health, and low-income nations can spend as little as $0.04. Median numbers of mental health professionals globally stand at only 13 per 100,000 people, and have made low- and middle-income nations critically short.

Access to treatment is most problematic in rural and underserved populations. In the United States, 65% of rural counties have no practicing psychiatrist, and nearly a third have no mental health professionals. Suburban residents, while otherwise better supplied, also experience affordability hurdles, insurance gaps, and cultural stigma, reducing meaningful access to care.

Progress and Persistent Gaps

There has been some progress. In the past two years, most countries have revised their mental health policies, improved emergency preparedness, and incorporated rights-based practices. More than 80% of nations now offer mental health services in emergencies, compared to 39% in 2020. Mental health integrated into primary care is making headway, and telehealth services are increasingly available.

Yet, these developments are insufficient to meet the global burden. Fewer than 10% of countries have fully transitioned to community-based care models, and inpatient care continues to rely heavily on psychiatric hospitals. Many patients experience long-term hospitalization, often involuntarily, highlighting the urgent need for systemic reform.

Why Addressing the Root Causes Is Important?

Mental health is a function of the complex interplay of social, environmental, and biological elements. Social media use, cyberbullying, and the pressure to maintain a "perfect" life on social media can contribute to exacerbating depression and anxiety. Economic insecurity, discrimination, trauma, and the residual effect of global crises such as the pandemic further add to the burden. Resolution of these foundational issues demands intersectoral collaboration—healthcare, education, social services, and policy.

Simple Tips for Improving Your Mental Health Everyday

Although reform on a wide scale is called for, people can also take actions to augment their mental health:

Stay Connected: Regular contact with others reduces loneliness.

Prioritize Physical Health: Exercise, healthy nutrition, and sleep contribute heavily to mood and cognitive performance.

Limit Digital Overload: Cut back on social media time, especially doomscrolling or comparing yourself to idealized models.

Practice Mindfulness: Meditation, journaling, or breathing exercises can reduce stress and enhance emotional resilience.

Get Professional Assistance: Therapy, counseling, or support groups provide direction and management techniques.

Foster Open Discussions: Open discussion of feelings within families, schools, or the workplace decreases stigma and promotes early intervention.

Crisis Hotlines: Familiarize yourself with local or national hotlines. For example, Kosovo provides Lifeline at 0800 12345 between the hours of 10:00 AM to 2:00 AM every day for crisis intervention.

The WHO underlines that mental health services should be addressed as a human right. Radical change to mental health services requires fair financing, legal changes to ensure human rights, and continued investment in the development of the workforce. Community-based, person-focused care models are essential to increase access and enhance outcomes. Multilevel collaboration between governments, NGOs, and international health agencies is required to address the breadth and depth of the crisis.

The current statistics present a grim picture: mental illness disorders are growing more quickly than world population growth, suicide is a leading cause of death among young people, and treatment access is starkly uneven. Unless drastic action is taken, the economic, social, and human toll will keep piling up.

Mental illness is not only a matter of health; it is a societal and economic problem that needs to be addressed immediately. Over one billion individuals are impacted globally, and younger generations disproportionately so. Progress has been made in policy, integration, and emergency response, yet never before has systemic reform and investment been as urgent a need. There is a role for every government, community, and individual in opening up access, decreasing stigma, and placing mental health as a top global public health priority.

The US Food and Drug Administration (FDA) has granted approval to Inlexzo (gemcitabine intravesical system) for the treatment of certain types of bladder cancer. This decision marks a milestone for patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle-invasive bladder cancer (NMIBC), particularly those living with carcinoma in situ (CIS), with or without papillary tumors.

Unlike systemic therapies, Inlexzo works through a novel drug-releasing intravesical system designed for extended local delivery of gemcitabine into the bladder. For patients who wish to preserve their bladder and avoid radical surgery, the approval opens a long-awaited alternative.

Bladder cancer is the sixth most common cancer in the United States, disproportionately affecting older adults. Patients with NMIBC often start with BCG immunotherapy, the gold standard treatment. While many respond well initially, a significant proportion develop resistance or fail to sustain remission.

For these patients, the only widely recommended option has been radical cystectomy—a surgery to remove the bladder. Though effective, the procedure carries high risks, including a 3–8 percent post-surgical mortality rate, long recovery periods, and significant impact on quality of life. Many older patients are either unfit or unwilling to undergo the operation.

What this really means is that patients who have exhausted BCG therapy have been left with limited, often life-altering choices. Inlexzo offers a chance to delay or avoid bladder removal while still pursuing effective treatment.

The FDA’s approval was based on results from the SunRISe-1 phase 2b trial, a single-arm, open-label study. Findings showed:

• 82 percent of patients achieved a complete response following treatment.
• 51 percent of those maintained their response for at least a year.

Dr. Sia Daneshmand, principal investigator of SunRISe-1 and a urologic oncologist at the University of Southern California, emphasized the significance of these results, “I see many patients that ultimately become BCG-unresponsive and often face life-altering bladder removal. In my experience, Inlexzo is well tolerated and delivers clinically meaningful results. This will change the way we treat appropriate patients that haven’t responded to traditional therapy.”

Such durability of response signals a meaningful step forward in NMIBC care, particularly for patients for whom cystectomy is not feasible.

What Is Non-Muscle-Invasive Bladder Cancer (NMIBC)?

NMIBC represents a subset of bladder cancers confined to the inner lining of the bladder wall. It is categorized as low, intermediate, or high risk, depending on tumor size, multiplicity, and the presence of CIS. Approximately 10 percent of NMIBC patients are diagnosed with CIS, a flat but aggressive form of cancer that requires close management.

The reliance on BCG has long been the standard of care, but when patients become unresponsive, treatment options have been scarce. Radical cystectomy has remained the fallback. The approval of Inlexzo helps close a treatment gap that has persisted for decades.

How Inlexzo Works?

Inlexzo is not a traditional infusion or oral drug. It uses a drug-eluting intravesical system, placed inside the bladder during a short, office-based procedure. It does not require general anesthesia and begins releasing gemcitabine immediately, maintaining extended exposure directly to the bladder tissue. This approach is significant for two reasons:

• It keeps the chemotherapy localized, limiting systemic exposure.
• It allows for continuous therapeutic action without repeated, invasive interventions.
• For many patients, this translates into a treatment that is not only effective but also easier to tolerate and less disruptive to daily life.

Risks, Safety, and Limitations

While Inlexzo is a major advancement, it is not without risks. The FDA has issued clear precautions:

• Patients with bladder perforations or compromised bladder lining should not receive Inlexzo, as systemic exposure to gemcitabine may cause severe reactions.
• Delaying cystectomy in patients with persistent CIS could increase the risk of progression to muscle-invasive or metastatic bladder cancer, which is often lethal.
• MRI safety is limited to specific conditions, requiring close adherence to guidelines.

Reproductive risks include embryo-fetal toxicity and potential male infertility, based on animal studies. Women are advised to avoid pregnancy during treatment and for at least a week after device removal.

The most common side effects include urinary frequency, infections, bladder irritation, and blood in the urine. Serious adverse events occurred in 24 percent of patients, with 1.2 percent experiencing fatal outcomes, though these were rare.

Is This System A Patient-Centered Shift in Bladder Cancer Care?

Bladder cancer disproportionately impacts older adults—72 percent of patients in the SunRISe-1 study were over 65 years old. For this group, surgery carries heightened risks. Inlexzo’s approval gives clinicians a new tool to help manage NMIBC without immediately resorting to bladder removal.

As Dr. Daneshmand noted, this drug-delivery innovation may change the treatment landscape by filling a crucial gap in care. For patients who have exhausted BCG and face limited choices, Inlexzo offers hope for improved survival and quality of life.

Inlexzo’s approval is a win not only for patients but also for the field of urologic oncology. The drug’s placement under Johnson & Johnson’s portfolio signals strong industry investment in localized, bladder-preserving therapies.

Experts caution, however, that long-term follow-up studies will be essential to fully understand Inlexzo’s durability, risks, and potential role in combination with other therapies. For now, the FDA’s decision gives patients an urgently needed option that bridges the gap between immunotherapy failure and radical surgery.

When it comes to tackling chronic disease, the United States is lagging behind its peers. A new study published in The Lancet reveals that among 25 high-income Western countries, the US has shown the slowest progress in reducing deaths from noncommunicable diseases such as cancer, heart disease, stroke, and diabetes.

The research, led by Imperial College London, analyzed mortality data from 185 countries between 2010 and 2019. While most nations reported overall declines in the probability of dying before age 80 from chronic disease, the US not only saw smaller reductions compared with other wealthy countries but also a troubling rise in deaths among younger adults aged 20 to 45.

The data show that between 2010 and 2019, deaths from chronic disease decreased in most US age groups but increased among young adults, a rare and alarming trend for a high-income country. Researchers describe this as “a rare phenomenon in high-income Western countries,” suggesting that the problem is systemic, not just demographic.

Majid Ezzati, the study’s senior author and professor of global health at Imperial, explained that while older Americans benefited from improved treatments and detection for heart disease and cancer, younger generations faced new and worsening risks including obesity, alcohol use disorders, and neuropsychiatric conditions like dementia.

The global picture provides a stark contrast. Roughly 80 percent of countries saw reductions in chronic disease mortality during the past decade, covering more than 70 percent of the world’s population. Denmark led the high-income group with the steepest decline, followed closely by Norway and Finland. Germany performed poorly as well, showing only slightly better results than the US.

While all high-income countries experienced a slowdown in the rate of decline compared to earlier decades, the United States stood out for its stagnation in working-age adults and actual increases in younger adults. Other countries managed to balance slower declines in older age groups with sharper improvements in working-age populations, but the US did not.

Why Is the US Falling Behind in Mortality?

The study did not dive into root causes, but experts point to a combination of health system and social factors:

Healthcare access and disparities: Millions of Americans lack consistent primary care, delaying diagnosis and treatment of chronic conditions. Without a physician close to home, routine screenings often fall through the cracks.

Social determinants of health: Income inequality, food insecurity, and limited access to healthy lifestyles all disproportionately affect younger and working-age adults.

Rise in neuropsychiatric conditions: While cancer and heart disease deaths declined, increases in dementia, alcohol use disorders, and mental health-related conditions offset gains.

Obesity and lifestyle factors: Rising rates of obesity, poor diets, and sedentary behavior have made chronic diseases harder to control, particularly among younger people.

Ezzati emphasized that underinvestment in public health is a common denominator. “In both the US and Germany, there are segments of the population in which there has been less investment in public health, and these disparities in investment can lead to broad barriers to accessing care,” he said.

Is This A Global Slowdown, Not Just an American Problem?

The US may be the slowest among wealthy nations, but it is not alone in struggling. Nearly two-thirds of all countries saw slower progress in reducing chronic disease mortality during 2010–2019 compared with the previous decade.

In northern Europe, for example, Denmark and Finland reported slower improvements among older adults, but these were offset by faster progress among working-age adults. That balance prevented them from stagnating as the US did.

Globally, the slowdown raises concerns about whether countries will meet the UN Sustainable Development Goal of reducing premature mortality from noncommunicable diseases by one-third by 2030.

So what sets top performers like Denmark apart? Researchers credit strong investment in preventive health, early detection, and broad access to primary care. Comprehensive strategies for cardiovascular disease prevention, aggressive anti-smoking campaigns, and early cancer screening programs have made a measurable impact.

By contrast, the US has struggled to implement nationwide preventive programs. Even when effective interventions exist — like lifestyle counseling, preventive screenings, and access to affordable medications, barriers in insurance coverage, geography, and affordability keep many Americans from benefiting.

Perhaps the most sobering aspect of the study is that progress is slowing not just in the US but worldwide. Improvements in diagnosis and treatment that once drove sharp declines in chronic disease deaths may be reaching their limits. Unless new strategies are adopted — especially those that reach disadvantaged populations — gains could stall entirely or even reverse.

For the US, where chronic diseases already account for 6 in 10 deaths, the message is clear: without significant investment in prevention and equitable healthcare access, the gap with peer nations will only widen.

Ezzati summed up the findings with a blunt warning, “The risk of dying from chronic diseases in most countries in the world is coming down. But we were doing better before.”

The All India Institute of Medical Sciences (AIIMS) in New Delhi has created a new mental health program called "Never Alone." The program was launched on World Suicide Prevention Day to directly address the serious issue of student suicides and to improve mental health awareness.

"Never Alone" is an AI-based tool designed to help students who may be struggling with suicidal thoughts and other mental health challenges. Its main goal is to reduce the negative social stigma that often prevents people from seeking help and to make it easier for them to access professional support.

How the App Works?

The "Never Alone" app is a very secure and personalized program that students can use anytime, day or night. It works through a web app that can be easily accessed via WhatsApp. For a very low cost of just 70 paisa per student per day, institutions can subscribe to the service and offer it to their students.

Also Read: Physiotherapists Are Not Doctors, Cannot Use ‘Dr’ Title, Rules Health Authority In India

The app provides a secure mental health screening and gives students access to both online and in-person consultations with trained mental health experts. This setup makes getting help more convenient and private, which can be very important for students who might feel uncomfortable talking about their struggles in person.

Growing Crisis Among Young Adults

This program was launched to tackle a serious national problem. According to government data, in 2022, more than 1.7 lakh people died by suicide in India. What's especially concerning is that a large portion of these deaths—35%—were among young adults between the ages of 18 and 30.

Experts say a big reason for this is that many people with mental health issues don't get the help they need. This is often due to a lack of awareness and the fear of being judged by others. The "Never Alone" app aims to fill this gap by providing a confidential and accessible way for students to get support.